On July 31, according to Xinghan Capital, Chengdu Biyang Pharmaceutical Technology Co., Ltd. recently announced that it has overcompleted Series A financing of nearly 200 million yuan. This round of financing was jointly led by Junlian Capital and the Shanghai Biomedical Innovation and Transformation Fund, followed by Kangzhe Pharmaceutical, Fenglei Capital, Shanghai Science and Technology Innovation Fund, and Hong Kong and Guangdong Capital. The old shareholder Yuanjinchuang continued to increase its investment in Yuansheng Venture Capital, and Xinghan Capital acted as the financial advisor for this round of financing. This round of funding will mainly be used to accelerate the technical iteration of the company's core AI+ molecular design and optimization platform, promote clinical and pre-clinical development of key project pipelines, and further improve international R&D and business team building.

On July 31, according to Xinghan Capital, Chengdu Biyang Pharmaceutical Technology Co., Ltd. recently announced that it has overcompleted Series A financing of nearly 200 million yuan. This round of financing was jointly led by Junlian Capital and the Shanghai Biomedical Innovation and Transformation Fund, followed by Kangzhe Pharmaceutical, Fenglei Capital, Shanghai Science and Technology Innovation Fund, and Hong Kong and Guangdong Capital. The old shareholder Yuanjinchuang continued to increase its investment in Yuansheng Venture Capital, and Xinghan Capital acted as the financial advisor for this round of financing. This round of funding will mainly be used to accelerate the technical iteration of the company's core AI+ molecular design and optimization platform, promote clinical and pre-clinical development of key project pipelines, and further improve international R&D and business team building.